Physician profile
Eric K Fleming
NPI 1528279650
$1,489.77
in general payments reported to CMS, 2019-2025
13 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $454 · 2021: $193 · 2022: $236 · 2023: $125 · 2024: $81.72 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $462.94 | 2019-2025 | Acuvue |
| Glaukos Corporation | $219.49 | 2020 | |
| Abb Con-Cise Optical Group LLC | $166.77 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $152.69 | 2023-2025 | Infuse Multifocal, Infuse, Xiidra |
| Alcon Vision LLC | $149.95 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $142.64 | 2019-2020 | |
| Coopervision INC. | $91.54 | 2022-2025 | Myday Contact Lens |
| Allergan, INC. | $37.93 | 2021 | |
| Horizon Therapeutics Plc | $23.25 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $15.98 | 2024 | Tyrvaya |
| Lombart Brothers, INC. | $12.07 | 2019 | |
| Rxsight INC | $11.82 | 2022 | |
| Visioneering Technologies, INC. | $2.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.